37. Generalised pustular psoriasis
58 clinical trials,   50 drugs   (DrugBank: 18 drugs),   17 drug target genes,   96 drug target pathways

Searched query = "Generalised pustular psoriasis", "Pustular psoriasis", "Herpetic impetigo", "Generalization of acrodermatitis continua", "Generalization of dermatitis continua of the extremities"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-003922-70-DE
(EUCTR)
28/11/200708/08/2007Uncontrolled, open Phase IIa study to investigate efficacy and safety of efalizumab in patients with moderate to severe palmoplantar pustular psoriasis (PPP) - PPP StudyUncontrolled, open Phase IIa study to investigate efficacy and safety of efalizumab in patients with moderate to severe palmoplantar pustular psoriasis (PPP) - PPP Study moderate to severe palmoplantar pustular psoriasis
MedDRA version: 9.1;Level: LLT;Classification code 10037159;Term: Psoriasis pustular
Trade Name: Raptiva
INN or Proposed INN: Efalizumab
Technische Universität DresdenNULLNot RecruitingFemale: yes
Male: yes
42Phase 2aGermany